Allonnia

Allonnia was launched in October 2020 as a spinout from Ginkgo Bioworks, the publicly traded synthetic biology platform, with Series A funding and a mandate to commercialize bioremediation technologies. It operates as an independent company with its own leadership, board, and facilities in Boston, but leverages Ginkgo's foundational cell-engineering infrastructure for organism discovery and design.

CEO Nicole Richards runs the firm's overall strategy, bringing more than 28 years of industry leadership from DuPont Water Solutions and Solvay. Operational decisions span a leadership team that includes a Chief Technical Officer, Chief Commercial Officer, and Chief Financial Officer. The board includes Tom Biegala of Bison Ventures, Marc Doyle, and mining advisor Dean Gehring.

Allonnia is not an investment fund — it is an operating company that generates revenue through commercial service contracts, co-development agreements with industrial partners, and government-funded demonstration projects. It uses raised capital to fund R&D, build field-deployable treatment units, and scale operations across North American job sites, including DoD facilities and active mine operations.

Allonnia targets two primary markets: PFAS treatment for groundwater, surface water, landfill leachate, and drinking water, and critical-mineral extraction focusing on nickel, copper, lithium, cobalt, gold, rare earth elements, and platinum group metals. It does not operate in pharmaceutical, agricultural biotechnology, or consumer-product sectors.

The firm emphasizes commercial readiness through its 'Integrated Systems' model, moving from environmental bioinformatics to transformative biology and then to deployable field units. By late 2025 it had treated over 146 million gallons of PFAS-contaminated water and completed its first mining biosolubilization demonstration at Eagle Mine, signaling a near-term deployment bias over long-horizon pure research.